{
  "metadata": {
    "case_id": 98,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T19:51:38.062022",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/98_NCT02910583.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/98_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 5,
      "similarity_matrix": [
        [
          0.96,
          0.33,
          0.82,
          0.78,
          0.88
        ],
        [
          0.9,
          0.62,
          0.96,
          0.82,
          0.7
        ],
        [
          0.72,
          0.96,
          0.82,
          0.68,
          0.55
        ],
        [
          0.82,
          0.62,
          0.78,
          0.9,
          0.78
        ],
        [
          0.94,
          0.4,
          0.78,
          0.7,
          0.97
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 420 mg of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment (ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule) for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax"
            ]
          },
          "pred_item": {
            "label": "Prerandomization Ibrutinib Lead-in then Ibrutinib plus Venetoclax",
            "type": "OTHER",
            "description": "All enrolled patients received first a prerandomization phase: oral ibrutinib 420 mg once daily for 3 cycles (28 days each) as single-agent lead-in for tumor debulking and TLS risk reduction, followed by 12 cycles of combined ibrutinib 420 mg once daily plus venetoclax (ramped up over 5 weeks to a target dose of 400 mg once daily) with TLS prophylaxis and monitoring per venetoclax prescribing information.",
            "interventionNames": [
              "Ibrutinib",
              "Venetoclax",
              "Tumor lysis syndrome prophylaxis and monitoring"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).\n\nParticipants with confirmed uMRD are randomized to receive ibrutinib 420 mg orally once daily on a continuous schedule until MRD-positive relapse, disease progression (PD), or unacceptable toxicity.\n\nAfter MRD-positive relapse or disease progression (PD) by iwCLL criteria, participants can reintroduce 400 mg venetoclax with a 5-week ramp up. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax"
            ]
          },
          "pred_item": {
            "label": "Confirmed uMRD – Ibrutinib",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients with confirmed uMRD in both peripheral blood and bone marrow after the prerandomization phase were randomized 1:1. In this arm, patients continued oral ibrutinib 420 mg once daily in a double‑blind fashion versus placebo, starting after the completion of 3 cycles of ibrutinib lead‑in and 12 cycles of ibrutinib plus venetoclax, and were treated until confirmed MRD relapse or disease progression.",
            "interventionNames": [
              "Ibrutinib",
              "Venetoclax",
              "Tumor lysis syndrome prophylaxis and monitoring"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase).\n\nParticipants with confirmed uMRD are randomized to receive placebo orally once daily on a continuous schedule until MRD-positive relapse, PD or unacceptable toxicity.\n\nIf MRD-positive relapse or PD is confirmed after restaging per iwCLL criteria, participants can first reintroduce oral daily ibrutinib with the option of subsequently reintroducing 400 mg venetoclax with a 5-week ramp up, if subsequent disease relapse per iwCLL criteria occurs after ibrutinib reintroduction. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax",
              "Drug: Placebo"
            ]
          },
          "pred_item": {
            "label": "Confirmed uMRD – Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients who achieved confirmed undetectable MRD (uMRD) in both peripheral blood and bone marrow after the prerandomization phase, defined as < 1 CLL cell per 10,000 leukocytes over at least 2 assessments ≥ 3 months apart, were randomized 1:1. In this arm, patients received oral placebo once daily in a double‑blind fashion instead of continued ibrutinib, until confirmed MRD relapse (≥ 1 CLL cell per 100 leukocytes on two occasions) or disease progression.",
            "interventionNames": [
              "Placebo",
              "Ibrutinib",
              "Venetoclax",
              "Tumor lysis syndrome prophylaxis and monitoring"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 3,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "label": "MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).\n\nParticipants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg orally once daily on a continuous schedule until PD or unacceptable toxicity.\n\nIn case of confirmed PD after restaging per iwCLL criteria, participants can continue ibrutinib and reintroduce venetoclax treatment. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax"
            ]
          },
          "pred_item": {
            "label": "uMRD Not Confirmed – Ibrutinib",
            "type": "EXPERIMENTAL",
            "description": "Patients who did not meet the strict criteria for confirmed uMRD (uMRD Not Confirmed population) after the prerandomization phase were randomized 1:1. In this arm, patients received open‑label single‑agent oral ibrutinib 420 mg once daily and discontinued venetoclax. Ibrutinib was continued until disease progression or unacceptable toxicity.",
            "interventionNames": [
              "Ibrutinib",
              "Venetoclax",
              "Tumor lysis syndrome prophylaxis and monitoring"
            ]
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 4,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "label": "MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)",
            "type": "EXPERIMENTAL",
            "description": "Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase).\n\nParticipants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. Venetoclax was allowed for administration up to 2 years cumulatively from first dose started in the pre-randomization phase to last dose in the randomization phase.",
            "interventionNames": [
              "Drug: ibrutinib",
              "Drug: venetoclax"
            ]
          },
          "pred_item": {
            "label": "uMRD Not Confirmed – Ibrutinib plus Venetoclax",
            "type": "EXPERIMENTAL",
            "description": "Patients who did not meet the strict criteria for confirmed uMRD (uMRD Not Confirmed population) after the prerandomization phase were randomized 1:1. In this arm, patients continued open‑label combination therapy with oral ibrutinib 420 mg once daily plus venetoclax (target dose 400 mg once daily, with a total venetoclax exposure capped at 2 years overall) until disease progression or unacceptable toxicity.",
            "interventionNames": [
              "Ibrutinib",
              "Venetoclax",
              "Tumor lysis syndrome prophylaxis and monitoring"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.96,
          0.65,
          0.3,
          0.37
        ],
        [
          0.4,
          0.96,
          0.4,
          0.32
        ],
        [
          0.4,
          0.2,
          0.94,
          0.18
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "ibrutinib",
            "description": "ibrutinib administered orally once daily (three 140 mg capsules)",
            "armGroupLabels": [
              "Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax",
              "MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)",
              "MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)",
              "MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)",
              "MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Ibrutinib",
            "description": "Oral Bruton tyrosine kinase (BTK) inhibitor administered at 420 mg once daily. Used as single‑agent lead‑in for 3 cycles to debulk disease and reduce tumor lysis syndrome risk, then combined with venetoclax for 12 cycles, and continued as maintenance in selected randomized arms until MRD relapse or disease progression.",
            "armGroupLabels": [
              "Prerandomization Ibrutinib Lead-in then Ibrutinib plus Venetoclax",
              "Confirmed uMRD – Placebo",
              "Confirmed uMRD – Ibrutinib",
              "uMRD Not Confirmed – Ibrutinib",
              "uMRD Not Confirmed – Ibrutinib plus Venetoclax"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "venetoclax",
            "description": "venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.",
            "armGroupLabels": [
              "Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax",
              "MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)",
              "MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)",
              "MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)",
              "MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Venetoclax",
            "description": "Oral BCL-2 inhibitor administered with a standard 5‑week ramp‑up to a target dose of 400 mg once daily, given in combination with ibrutinib for 12 cycles during the prerandomization phase; in the uMRD Not Confirmed – Ibrutinib plus Venetoclax arm, venetoclax could be continued with ibrutinib up to a maximum overall venetoclax treatment duration of 2 years.",
            "armGroupLabels": [
              "Prerandomization Ibrutinib Lead-in then Ibrutinib plus Venetoclax",
              "Confirmed uMRD – Placebo",
              "Confirmed uMRD – Ibrutinib",
              "uMRD Not Confirmed – Ibrutinib",
              "uMRD Not Confirmed – Ibrutinib plus Venetoclax"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "placebo capsules to match ibrutinib administered orally once daily",
            "armGroupLabels": [
              "MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Oral placebo administered once daily in a double‑blind fashion as a comparator to continued ibrutinib in patients with confirmed uMRD after the combination phase, continued until MRD relapse or disease progression.",
            "armGroupLabels": [
              "Confirmed uMRD – Placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.96
        ],
        [
          0.18
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants",
            "description": "DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia \\[IWCLL\\] criteria \\[Halleck et al\\]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time.",
            "timeFrame": "1 year after randomization"
          },
          "pred_item": {
            "measure": "1-year disease-free survival rate in the Confirmed uMRD population",
            "description": "Disease-free survival (DFS) at 1 year after random assignment, defined as the absence of MRD relapse, disease progression, or death in patients with Confirmed undetectable minimal residual disease (uMRD) who were randomized to placebo or ibrutinib.",
            "timeFrame": "1 year after random assignment"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate",
            "description": "CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months."
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 24,
      "pred_count": 10,
      "similarity_matrix": [
        [
          0.4,
          0.35,
          0.86,
          0.9,
          0.22,
          0.25,
          0.25,
          0.1,
          0.08,
          0.08
        ],
        [
          0.35,
          0.38,
          0.9,
          0.6,
          0.3,
          0.18,
          0.18,
          0.2,
          0.08,
          0.05
        ],
        [
          0.32,
          0.3,
          0.4,
          0.35,
          0.94,
          0.12,
          0.32,
          0.38,
          0.18,
          0.08
        ],
        [
          0.92,
          0.88,
          0.4,
          0.3,
          0.08,
          0.15,
          0.31,
          0.1,
          0.1,
          0.08
        ],
        [
          0.15,
          0.25,
          0.18,
          0.1,
          0.07,
          0.96,
          0.05,
          0.05,
          0.35,
          0.1
        ],
        [
          0.4,
          0.32,
          0.15,
          0.2,
          0.55,
          0.1,
          0.93,
          0.35,
          0.05,
          0.08
        ],
        [
          0.25,
          0.2,
          0.25,
          0.08,
          0.18,
          0.08,
          0.4,
          0.96,
          0.12,
          0.08
        ],
        [
          0.18,
          0.1,
          0.05,
          0.08,
          0.06,
          0.12,
          0.05,
          0.05,
          0.93,
          0.25
        ],
        [
          0.3,
          0.3,
          0.88,
          0.72,
          0.55,
          0.12,
          0.25,
          0.1,
          0.1,
          0.1
        ],
        [
          0.08,
          0.12,
          0.68,
          0.55,
          0.96,
          0.1,
          0.62,
          0.42,
          0.07,
          0.05
        ],
        [
          0.94,
          0.9,
          0.4,
          0.4,
          0.12,
          0.2,
          0.18,
          0.05,
          0.08,
          0.08
        ],
        [
          0.1,
          0.1,
          0.2,
          0.1,
          0.42,
          0.08,
          0.96,
          0.55,
          0.08,
          0.05
        ],
        [
          0.08,
          0.08,
          0.08,
          0.08,
          0.18,
          0.08,
          0.65,
          0.94,
          0.08,
          0.05
        ],
        [
          0.18,
          0.15,
          0.2,
          0.12,
          0.05,
          0.97,
          0.08,
          0.12,
          0.18,
          0.12
        ],
        [
          0.05,
          0.05,
          0.12,
          0.07,
          0.05,
          0.06,
          0.05,
          0.18,
          0.93,
          0.22
        ],
        [
          0.18,
          0.2,
          0.08,
          0.05,
          0.05,
          0.12,
          0.08,
          0.08,
          0.1,
          0.82
        ],
        [
          0.18,
          0.1,
          0.02,
          0.07,
          0.05,
          0.12,
          0.08,
          0.08,
          0.15,
          0.9
        ],
        [
          0.12,
          0.08,
          0.05,
          0.05,
          0.05,
          0.12,
          0.05,
          0.07,
          0.18,
          0.86
        ],
        [
          0.08,
          0.21,
          0.08,
          0.05,
          0.03,
          0.12,
          0.02,
          0.05,
          0.2,
          0.88
        ],
        [
          0.2,
          0.2,
          0.08,
          0.05,
          0.06,
          0.05,
          0.05,
          0.05,
          0.12,
          0.88
        ],
        [
          0.18,
          0.1,
          0.1,
          0.05,
          0.02,
          0.12,
          0.05,
          0.07,
          0.08,
          0.86
        ],
        [
          0.1,
          0.18,
          0.06,
          0.08,
          0.04,
          0.15,
          0.07,
          0.08,
          0.15,
          0.86
        ],
        [
          0.18,
          0.15,
          0.08,
          0.08,
          0.05,
          0.18,
          0.05,
          0.05,
          0.08,
          0.86
        ],
        [
          0.12,
          0.22,
          0.1,
          0.03,
          0.02,
          0.12,
          0.1,
          0.05,
          0.12,
          0.84
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 3,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: CRR (CR/CRi Rate)",
            "description": "CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": {
            "measure": "Complete response rate (including CR with incomplete bone marrow recovery)",
            "description": "Proportion of patients achieving a best response of complete response (CR) or CR with incomplete bone marrow recovery (CRi) per 2008 iwCLL criteria.",
            "timeFrame": "From first dose of study treatment through completion of study treatment and follow-up"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: Overall Response Rate (ORR)",
            "description": "ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": {
            "measure": "Overall response rate",
            "description": "Proportion of patients achieving a best overall response of complete response, complete response with incomplete bone marrow recovery, partial response, or nodular partial response per 2008 iwCLL criteria by investigator assessment.",
            "timeFrame": "From first dose of study treatment through completion of study treatment and follow-up"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Duration of Response (DOR) at 42 Months Landmark Time",
            "description": "Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of 67.0 months study follow-up, the Kaplan-Meier estimate of DOR at 42 months landmark time was presented.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From initial documentation of a response until PD or death from any cause, whichever occurs first, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": 0,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: MRD-Negativity Rate",
            "description": "MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \\<1 CLL cell per 10,000 leukocytes (\\<1 x 10\\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From randomization date until before any subsequent antineoplastic therapy, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": {
            "measure": "Undetectable minimal residual disease (uMRD) rate in peripheral blood",
            "description": "Proportion of patients achieving undetectable MRD in peripheral blood, generally defined as fewer than 1 CLL cell per 10,000 leukocytes by flow cytometry.",
            "timeFrame": "During prerandomization phase after 12 cycles of ibrutinib plus venetoclax and over follow-up"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)",
            "description": "TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \\< 5 cm AND absolute lymphocyte count (ALC) \\< 25 x 10\\^9/L; Medium=Any LN 5 cm to \\< 10 cm OR ALC ≥ 25 x 10\\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\\^9/L AND any LN ≥ 5 cm.",
            "timeFrame": "Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib)."
          },
          "pred_item": null
        },
        {
          "ref_idx": 5,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 48 Months Landmark Time",
            "description": "PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 48 months landmark time was presented.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD or death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 6,
          "pred_idx": 7,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 48 Months Landmark Time",
            "description": "OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 48 months landmark time was presented.\n\nMedian follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD: Randomized to Ibrutinib=69.1 months; Confirmed uMRD: Randomized to Placebo=67.4 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib=47.9 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax=47.9 months.",
            "timeFrame": "From the first dose of ibrutinib to time of death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)"
          },
          "pred_item": {
            "measure": "Overall survival",
            "description": "Time from first dose of study treatment to death from any cause.",
            "timeFrame": "From first dose of study treatment through end of follow-up"
          }
        },
        {
          "ref_idx": 7,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Discontinuations Due to TEAEs",
            "description": "An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \\>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.",
            "timeFrame": "From first dose until 30 days following last dose of study drug. Overall median treatment duration for the MRD cohort was 45.1 months."
          },
          "pred_item": null
        },
        {
          "ref_idx": 8,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "FD Cohort: ORR",
            "description": "ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months."
          },
          "pred_item": null
        },
        {
          "ref_idx": 9,
          "pred_idx": 4,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: DOR at 60 Months Landmark Time",
            "description": "Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 60 months landmark time was presented.",
            "timeFrame": "From initial documentation of a response until PD or death from any cause, whichever occurs first, for a median follow-up of 69.0 months."
          },
          "pred_item": {
            "measure": "Duration of response",
            "description": "Time from first documented achievement of objective response (CR, CRi, PR, or nodular PR) to documented disease progression or death.",
            "timeFrame": "From first documented response until disease progression or death, whichever occurs first"
          }
        },
        {
          "ref_idx": 10,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: MRD Negativity Rate",
            "description": "MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \\<1 CLL cell per 10,000 leukocytes (\\<1 x 10\\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier.",
            "timeFrame": "From randomization date until before any subsequent antineoplastic therapy, for a median follow-up of 69.0 months."
          },
          "pred_item": {
            "measure": "Undetectable minimal residual disease (uMRD) rate in bone marrow",
            "description": "Proportion of patients achieving undetectable MRD in bone marrow, generally defined as fewer than 1 CLL cell per 10,000 leukocytes by flow cytometry.",
            "timeFrame": "During prerandomization phase after 12 cycles of ibrutinib plus venetoclax and over follow-up"
          }
        },
        {
          "ref_idx": 11,
          "pred_idx": 6,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: Kaplan-Meier Estimate of PFS Rate at 66 Months Landmark Time",
            "description": "PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 66 months landmark time was presented.",
            "timeFrame": "From the first dose of ibrutinib to the first confirmed PD or death, for an median follow-up of 69.0 months."
          },
          "pred_item": {
            "measure": "Progression-free survival",
            "description": "Time from first dose of study treatment to disease progression or death from any cause.",
            "timeFrame": "From first dose of study treatment through end of follow-up"
          }
        },
        {
          "ref_idx": 12,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "FD Cohort: Kaplan-Meier Estimate of OS Rate at 66 Months Landmark Time",
            "description": "OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 66 months landmark time was presented.",
            "timeFrame": "From the first dose of ibrutinib to time of death, for a median follow-up of 69.0 months."
          },
          "pred_item": null
        },
        {
          "ref_idx": 13,
          "pred_idx": 5,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)",
            "description": "TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \\< 5 cm AND absolute lymphocyte count (ALC) \\< 25 x 10\\^9/L; Medium=Any LN 5 cm to \\< 10 cm OR ALC ≥ 25 x 10\\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\\^9/L AND any LN ≥ 5 cm.",
            "timeFrame": "Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib)."
          },
          "pred_item": {
            "measure": "Tumor lysis syndrome (TLS) risk category reduction after ibrutinib lead-in",
            "description": "Proportion of patients categorized as high risk for TLS at baseline who shift to medium or low TLS risk categories following three cycles of single-agent ibrutinib lead-in, based on tumor burden and venetoclax prescribing information.",
            "timeFrame": "Baseline (before ibrutinib) and after completion of 3 cycles of ibrutinib lead-in, before venetoclax initiation"
          }
        },
        {
          "ref_idx": 14,
          "pred_idx": 8,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "FD Cohort: Percentage of Participants With TEAEs, Treatment-Emergent SAEs, and Discontinuations Due to TEAEs",
            "description": "An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \\>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.",
            "timeFrame": "From first dose until 30 days following last dose of study drug. Overall median treatment duration for the FD cohort was 13.8 months."
          },
          "pred_item": {
            "measure": "Safety and tolerability",
            "description": "Incidence, severity, and type of adverse events, including serious adverse events, grade ≥3 events, atrial fibrillation, major hemorrhage, infections, tumor lysis syndrome, and adverse events leading to dose modification or discontinuation of ibrutinib or venetoclax.",
            "timeFrame": "From first dose of study treatment through the treatment period and safety follow-up at every visit"
          }
        },
        {
          "ref_idx": 15,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 16,
          "pred_idx": 9,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Time to Cmax (Tmax); Time of Last Measurable Concentration (Tlast); Terminal Elimination Half-Life (t1/2,Term)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": {
            "measure": "Pharmacokinetics of ibrutinib and venetoclax in combination",
            "description": "Plasma exposure parameters (e.g., area under the curve) of ibrutinib and venetoclax when administered together, and evaluation of any association between drug exposure and adverse events.",
            "timeFrame": "During single-agent ibrutinib lead-in and during combination ibrutinib plus venetoclax treatment (limited pharmacokinetic sampling)"
          }
        },
        {
          "ref_idx": 17,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Area Under the Plasma Concentration-Time Curve (AUC) Over the Last 24-hour Dosing Interval (AUC0-24h); AUC From Time Zero to the Time of Last Quantifiable Concentration (AUClast)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 18,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 19,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F)",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 20,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 21,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 22,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        },
        {
          "ref_idx": 23,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F",
            "timeFrame": "Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)"
          },
          "pred_item": null
        }
      ]
    }
  ]
}